サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1463062

急性反復性発作市場、シェア、規模、動向、産業分析レポート：製品別、最終用途別、地域別、およびセグメント別予測、2024年～2032年

Acute Repetitive Seizures Market Share, Size, Trends, Industry Analysis Report, By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel, Others); By End Use; By Region; And Segment Forecasts, 2024 - 2032

出版日
ページ情報
英文 114 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
急性反復性発作市場、シェア、規模、動向、産業分析レポート：製品別、最終用途別、地域別、およびセグメント別予測、2024年～2032年
出版日: 2024年03月24日
発行: Polaris Market Research
ページ情報: 英文 114 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の急性反復性発作の市場規模は2032年までに79億4,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

市場成長の原動力は、臨床研究の増加、新薬導入の注目の高まり、てんかん治療薬としての鼻腔スプレーの需要拡大です。さらに、規制当局の承認が増加し、有望な治療薬が開発中であることも、予測期間中の急性反復性発作市場の開拓に拍車をかけると予想されます。医療費抑制の取り組みと連動して、各国政府は在宅医療や診療所などの外来診療モデルの導入を通じて、入院や現場での治療費を最小限に抑えることに積極的に取り組んでいます。

希少疾病用医薬品は、大規模な商業化により世界市場を独占すると予想されます。USL-261とVALTOCOの両方が希少疾病用医薬品に指定されたことは、価格設定が上昇する可能性が高いことを示唆しています。さらに、他の投与方法よりも経鼻投与経路が好まれることも、これら2つの薬剤の利用拡大に寄与すると予想されます。安全で費用対効果の高い代替薬に対する需要の高まりから、点鼻薬による鼻腔経路投与の安全性と有効性を評価する臨床試験が急増しています。さらに、FDAの承認件数が増加していることから、間もなく革新的な薬剤が導入され、急性反復性発作市場に新たな成長機会がもたらされると期待されています。

欧州の成長は、てんかん治療薬の需要増と相まって、神経学の研究開発への投資が活発化していることに起因しています。さらに、科学、治療、医療分野における技術の進歩も、この成長に寄与するものと思われます。同時に、QOLの向上、疾患に対する認識向上、ヘルスケア施設の整備を目的とした政府の取り組みが、同地域での市場拡大を促進する主要因となっています。

新興国を含む世界各国の政府は、医療費の増加に対処するため、ヘルスケア改革を積極的に推進しています。こうした改革の重要な側面のひとつは、診療所や在宅ヘルスケアなどの外来診療モデルの導入による入院期間と現場での治療費の削減です。このアプローチの背景には、ヘルスケアサービスをより費用対効果が高く、利用しやすく、患者中心のものにするという理論的根拠があります。ヘルスケア改革は、治療へのアクセシビリティの向上、病院資源への負担の軽減、患者の転帰の改善につながります。新興国の政府がこのような改革の実施に注力する中、外来患者ケアモデルの成長は、患者ケアにより効率的で費用対効果の高い手段を提供することで、市場の拡大を促進すると予想されます。

急性反復性発作市場レポートハイライト

2023年の市場シェアはUSL-261が最大、投与の簡便性からARSを含む急性発作群の管理にUSL-261が魅力的な選択肢に

ヘルスケア＆医薬品分野は予測期間中に最も速いCAGRで成長すると予想され、有利な規制政策と市場承認が革新的な治療法の商業化を促進し、市場成長に寄与します。

北米、特に米国の規制環境は、ヘルスケア分野の技術革新と市場拡大に寄与しています。食品医薬品局（FDA）などの規制機関は、ARS治療法の開発と承認に明確なガイドラインと経路を提供しており、市場成長を促進しています。

アジア太平洋地域は、予測期間中に最も速いCAGRで成長すると予想されます。ヘルスケアインフラへの重点的な取り組みが進み、てんかんに対する意識が高まっていることが、新興国市場の成長に有利な条件となっています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 急性反復性発作の世界市場の洞察

  • 急性反復性発作市場- 業界スナップショット
  • 急性反復性発作市場力学
    • 促進要因と機会
      • 神経疾患の有病率の上昇が市場の成長を促進すると予測されている
      • 世界中でてんかんの発症率が増加していることは、ARSの有病率の増加に直接寄与しています。
    • 抑制要因と課題
      • 専門的な診断検査やモニタリング機器の利用可能性が限られている
  • PESTLE分析
  • 急性反復性発作業界の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 製品別の世界市場

  • 主な調査結果
  • イントロダクション
  • USL-261
  • NRL-1
  • AZ-002
  • ディアスタット直腸ジェル
  • その他

第6章 最終用途別の世界市場

  • 主な調査結果
  • イントロダクション
  • バイオテクノロジー
  • ヘルスケアと医薬品
  • その他

第7章 地域別の世界市場

  • 主な調査結果
  • イントロダクション
    • 急性反復性発作市場評価、地域別、2019-2032年
  • 急性反復性発作市場-北米
    • 北米：急性反復性発作市場、最終用途別、2019年～2032年
    • 北米：急性反復性発作市場、製品別、2019年～2032年
    • 急性反復性発作市場-米国
    • 急性反復性発作市場- カナダ
  • 急性反復性発作市場- 欧州
    • 欧州：急性反復性発作市場、最終用途別、2019年～2032年
    • 欧州：急性反復性発作市場、製品別、2019年～2032年
    • 急性反復性発作市場- 英国
    • 急性反復性発作市場- フランス
    • 急性反復性発作市場- ドイツ
    • 急性反復性発作市場- イタリア
    • 急性反復性発作市場- スペイン
    • 急性反復性発作市場- オランダ
    • 急性反復性発作市場- ロシア
  • 急性反復性発作市場- アジア太平洋地域
    • アジア太平洋地域：急性反復性発作市場、最終用途別、2019年～2032年
    • アジア太平洋地域：急性反復性発作市場、製品別、2019年～2032年
    • 急性反復性発作市場- 中国
    • 急性反復性発作市場- インド
    • 急性反復性発作市場- マレーシア
    • 急性反復性発作市場- 日本
    • 急性反復性発作市場- インドネシア
    • 急性反復性発作市場- 韓国
  • 急性反復性発作市場-中東およびアフリカ
    • 中東およびアフリカ：急性反復性発作市場、最終用途別、2019-2032年
    • 中東およびアフリカ：急性反復性発作市場、製品別、2019-2032年
    • 急性反復性発作市場- サウジアラビア
    • 急性反復性発作市場-UAE
    • 急性反復性発作市場- イスラエル
    • 急性反復性発作市場- 南アフリカ
  • 急性反復性発作市場-ラテンアメリカ
    • ラテンアメリカ：急性反復性発作市場、最終用途別、2019年～2032年
    • ラテンアメリカ：急性反復性発作市場、製品別、2019年～2032年
    • 急性反復性発作市場- メキシコ
    • 急性反復性発作市場- ブラジル
    • 急性反復性発作市場- アルゼンチン

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/契約/公開

第9章 企業プロファイル

  • ALEXZA
  • Alexza Pharmaceuticals
  • Bausch Health Companies Inc.
  • Neurelis, Inc.
  • Pfizer Inc.
  • Sanofi
  • UCB S.A. Belgium
  • Valeant Pharmaceuticals North America LLC.
  • VERITON PHARMA
図表

List of Tables

  • Table 1 Global Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 2 Global Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 3 Acute Repetitive Seizures Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 5 North America: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 6 U.S.: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 7 U.S.: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 8 Canada: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 9 Canada: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 10 Europe: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 11 Europe: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 12 UK: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 13 UK: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 14 France: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 15 France: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 16 Germany: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 17 Germany: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 18 Italy: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 19 Italy: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 20 Spain: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 21 Spain: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 24 Russia: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 25 Russia: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 28 China: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 29 China: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 30 India: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 31 India: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 34 Japan: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 35 Japan: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 38 South Korea: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 39 South Korea: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 44 UAE: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 45 UAE: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 46 Israel: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 47 Israel: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 48 South Africa: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 49 South Africa: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 50 Latin America: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 51 Latin America: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 52 Mexico: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 53 Mexico: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 54 Brazil: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 55 Brazil: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • Table 56 Argentina: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • Table 57 Argentina: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Acute Repetitive Seizures Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by End Use
  • Figure 7 Global Acute Repetitive Seizures Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Product
  • Figure 9 Global Acute Repetitive Seizures Market, by Product, 2022 & 2032 (USD Billion)
  • Figure 10 Acute Repetitive Seizures Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Acute Repetitive Seizures Market
目次
Product Code: PM4747

The global acute repetitive seizures market size is expected to reach USD 7.94 billion by 2032, according to a new study by Polaris Market Research. The report "Acute Repetitive Seizures Market Share, Size, Trends, Industry Analysis Report, By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel, Others); By End Use; By Region; And Segment Forecasts, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growth of the market is driven by an increasing number of clinical studies, a heightened focus on the introduction of new medicines, and a growing demand for nasal sprays as a treatment for epilepsy. Moreover, the upswing in regulatory approvals and promising treatments in the pipeline is anticipated to fuel the development of the acute repetitive seizures market over the projected period. In tandem with initiatives to curtail healthcare expenditure, governments are actively engaged in minimizing hospital stays and on-site treatment costs through the implementation of outpatient care models, including home healthcare and clinics.

Orphan drugs are anticipated to dominate the global market, driven by extensive commercialization. The designation of both USL-261 and VALTOCO as orphan drugs suggests that their pricing is likely to be elevated. Furthermore, the preference for the nasal route of administration over other methods is expected to contribute to the increased utilization of these two medications. The rising demand for safe and cost-effective alternatives has led to a surge in clinical trials assessing the safety and efficacy of nasal route administration through nasal sprays. Additionally, the increasing number of FDA approvals is expected to pave the way for the introduction of innovative medications soon, presenting new growth opportunities for the acute repetitive seizures market.

Europe's growth is attributed to heightened investment in neurology research and development, coupled with an increasing demand for epilepsy drugs. Additionally, advancements in technology within the scientific, therapeutic, and medical sectors are poised to contribute to this growth. Concurrently, government initiatives aimed at enhancing quality of life, raising awareness about the disease, and fostering improved healthcare facilities are the key drivers propelling market expansion in the region.

Governments worldwide, including emerging economies, are actively pursuing healthcare reforms to address rising healthcare costs. One significant aspect of these reforms involves reducing hospital stays and on-site treatment costs through the implementation of outpatient care models, such as clinics and home healthcare. The rationale behind this approach is to make healthcare services more cost-effective, accessible, and patient-centric. Healthcare reforms can lead to increased accessibility to treatment, reduced burdens on hospital resources, and improved patient outcomes. As governments in emerging economies focus on implementing such reforms, the growth of outpatient care models is expected to propel the expansion of the market by providing more efficient and cost-effective avenues for patient care.

Acute Repetitive Seizures Market Report Highlights

USL-261 segment held the largest market share in 2023, the convenience of administration makes USL-261 an attractive option for managing acute seizure clusters, including those characteristics of ARS

Healthcare & pharmaceuticals segment is expected to grow at the fastest CAGR during the forecast period, Favorable regulatory policies and market approvals facilitate the commercialization of innovative treatments, contributing to market growth.

North America region held the largest market share in 2023, The regulatory environment in North America, particularly in the United States, is conducive to innovation and market expansion in the healthcare sector. Regulatory agencies such as the Food and Drug Administration (FDA) provide clear guidelines and pathways for the development and approval of ARS treatments, facilitating market growth.

Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The increased focus on healthcare infrastructure and rising awareness about epilepsy contribute to the favorable conditions for market growth in these developing nations.

The global players include ALEXZA, Alexza Pharmaceuticals, Bausch Health Companies Inc., Neurelis, Inc., Pfizer Inc., Sanofi, UCB S.A. Belgium, Valeant Pharmaceuticals North America LLC., VERITON PHARMA.

Acute Repetitive Seizures Market Research has segmented the acute repetitive seizures market report based on product, end use, and region:

Acute Repetitive Seizures, Product Outlook (Revenue - USD Billion, 2019 - 2032)

  • USL-261
  • NRL-1
  • AZ-002
  • Diastat Rectal Gel
  • Others

Acute Repetitive Seizures, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Biotechnology
  • Healthcare & pharmaceuticals
  • Others

Acute Repetitive Seizures, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of LA
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Acute Repetitive Seizures Market Insights

  • 4.1. Acute Repetitive Seizures Market - Industry Snapshot
  • 4.2. Acute Repetitive Seizures Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Prevalence of Neurological Disorders is projected to spur the market growth
      • 4.2.1.2. The rising incidence of epilepsy cases worldwide directly contributes to the increasing prevalence of ARS
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited availability of specialized diagnostic tests or monitoring devices
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Acute Repetitive Seizures Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Acute Repetitive Seizures Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Acute Repetitive Seizures, by Product, 2019-2032 (USD Billion)
  • 5.3. USL-261
    • 5.3.1. Global Acute Repetitive Seizures Market, by USL-261, by Region, 2019-2032 (USD Billion)
  • 5.4. NRL-1
    • 5.4.1. Global Acute Repetitive Seizures Market, by NRL-1, by Region, 2019-2032 (USD Billion)
  • 5.5. AZ-002
    • 5.5.1. Global Acute Repetitive Seizures Market, by AZ-002, by Region, 2019-2032 (USD Billion)
  • 5.6. Diastat Rectal Gel
    • 5.6.1. Global Acute Repetitive Seizures Market, by Diastat Rectal Gel, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Acute Repetitive Seizures Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Acute Repetitive Seizures Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
  • 6.3. Biotechnology
    • 6.3.1. Global Acute Repetitive Seizures Market, by Biotechnology, by Region, 2019-2032 (USD Billion)
  • 6.4. Healthcare & pharmaceuticals
    • 6.4.1. Global Acute Repetitive Seizures Market, by Healthcare & pharmaceuticals, by Region, 2019-2032 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Acute Repetitive Seizures Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Acute Repetitive Seizures Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Acute Repetitive Seizures Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Acute Repetitive Seizures Market - North America
    • 7.3.1. North America: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
    • 7.3.2. North America: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.3.3. Acute Repetitive Seizures Market - U.S.
      • 7.3.3.1. U.S.: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.3.4. Acute Repetitive Seizures Market - Canada
      • 7.3.4.1. Canada: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • 7.4. Acute Repetitive Seizures Market - Europe
    • 7.4.1. Europe: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.4.3. Acute Repetitive Seizures Market - UK
      • 7.4.3.1. UK: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.4.4. Acute Repetitive Seizures Market - France
      • 7.4.4.1. France: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.4.5. Acute Repetitive Seizures Market - Germany
      • 7.4.5.1. Germany: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.4.6. Acute Repetitive Seizures Market - Italy
      • 7.4.6.1. Italy: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.4.7. Acute Repetitive Seizures Market - Spain
      • 7.4.7.1. Spain: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.4.8. Acute Repetitive Seizures Market - Netherlands
      • 7.4.8.1. Netherlands: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.4.9. Acute Repetitive Seizures Market - Russia
      • 7.4.9.1. Russia: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • 7.5. Acute Repetitive Seizures Market - Asia Pacific
    • 7.5.1. Asia Pacific: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.5.3. Acute Repetitive Seizures Market - China
      • 7.5.3.1. China: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.5.4. Acute Repetitive Seizures Market - India
      • 7.5.4.1. India: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.5.5. Acute Repetitive Seizures Market - Malaysia
      • 7.5.5.1. Malaysia: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.5.6. Acute Repetitive Seizures Market - Japan
      • 7.5.6.1. Japan: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.5.7. Acute Repetitive Seizures Market - Indonesia
      • 7.5.7.1. Indonesia: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.5.8. Acute Repetitive Seizures Market - South Korea
      • 7.5.8.1. South Korea: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • 7.6. Acute Repetitive Seizures Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.6.3. Acute Repetitive Seizures Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.6.4. Acute Repetitive Seizures Market - UAE
      • 7.6.4.1. UAE: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.6.5. Acute Repetitive Seizures Market - Israel
      • 7.6.5.1. Israel: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.6.6. Acute Repetitive Seizures Market - South Africa
      • 7.6.6.1. South Africa: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
  • 7.7. Acute Repetitive Seizures Market - Latin America
    • 7.7.1. Latin America: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.7.3. Acute Repetitive Seizures Market - Mexico
      • 7.7.3.1. Mexico: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.7.4. Acute Repetitive Seizures Market - Brazil
      • 7.7.4.1. Brazil: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)
    • 7.7.5. Acute Repetitive Seizures Market - Argentina
      • 7.7.5.1. Argentina: Acute Repetitive Seizures Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Acute Repetitive Seizures Market, by Product, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. ALEXZA
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Alexza Pharmaceuticals
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bausch Health Companies Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Neurelis, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Pfizer Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Sanofi
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. UCB S.A. Belgium
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Valeant Pharmaceuticals North America LLC.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. VERITON PHARMA
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development